Equities researchers at Wedbush decreased their FY2025 earnings estimates for shares of Replimune Group in a research report ...

Replimune Group, Inc. (REPL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Shares of NASDAQ REPL opened at $13.75 on Wednesday. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a market capitalization of $940.78 million, a price-to ...

Barclays analyst Peter Lawson maintained a Buy rating on Replimune Group (REPL – Research Report) today and set a price target of $17.00. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...

Replimune Group (REPL) has disclosed a new risk, in the Share Price & Shareholder Rights category. Replimune Group faces a range of material risks ...

Short interest in Replimune Group Inc (NASDAQ:REPL) increased during the last reporting period, rising from 5.93M to 6.61M. This put 11.84% of the company's publicly available shares short.

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...